Jeff Jones Analyst PerformanceManaging Director - Senior Analyst at OppenheimerJeff Jones is a stock analyst at Oppenheimer focused in the medical sector, covering 10 publicly traded companies. Over the past year, Jeff Jones has issued 16 stock ratings, including and buy recommendations. While full access to Jeff Jones' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jeff Jones' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings17 Last 4 YearsBuy Recommendations100.00% 17 Buy RatingsCompanies Covered10 Unique Companies Ratings Distribution17RatingsDistribution of strong buy, buy, hold, and sell ratings by Jeff Jones.RatingPercentageCount Strong Buy0.0%0 ratings Buy100.0%17 ratings Hold0.0%0 ratings Sell0.0%0 ratingsthe majority (100.0%) have been Buy recommendations.Best & Worst CallsBest Call000.0%CMMBJul 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ90.0% of companies on NASDAQ9 companiesNYSE10.0% of companies on NYSE1 companyJeff Jones, an analyst at Oppenheimer, currently covers 10 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical9 companies90.0%Computer and Technology1 company10.0%Jeff Jones of Oppenheimer specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE8 companies80.0%MED - DRUGS1 company10.0%INTERNET SOFTWARE1 company10.0% About Jeff JonesJeff Jones is a Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Jeff founded and ran One Health Advisors, LLC which provided strategic advisory services for the human and animal biopharma sector. Prior to founding One Health, Jeff had served in numerous roles with biotechnology companies, including Vice President of Business Development at Aratana Therapeutics and COO at Pharmathene. Jeff received an B.A. in Biology from University of Virginia and a Ph.D. in Cell & Molecular Biology from Baylor College of Medicine. He has also completed an M.B.A. at Cornell University, Johnson Graduate School of Management.Follow on LinkedIn Jeff Jones' Ratings History at Oppenheimer Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCMMBChemomab Therapeutics8/27/2025Boost Price Target$3.54$25.00Outperform$0.0000.00% ROICRBPCorbus Pharmaceuticals8/6/2025Lower Price Target$8.90$53.00Outperform$0.0000.00% ROIKYMRKymera Therapeutics6/27/2025Reiterated Rating$44.05$53.00Outperform$0.0000.00% ROIAVBPArriVent BioPharma6/24/2025Reiterated Rating$22.86$44.00Outperform$0.0000.00% ROIYMABY-mAbs Therapeutics5/29/2025Lower Price Target$4.87$15.00Outperform$0.0000.00% ROICMMBChemomab Therapeutics5/16/2025Lower Price Target$5.50$40.00Outperform$0.0000.00% ROIALMSAlumis5/15/2025Lower Price Target$5.23$25.00Outperform$0.0000.00% ROIYMABY-mAbs Therapeutics5/14/2025Lower Price Target$3.94$20.00Outperform$0.0000.00% ROICRVSCorvus Pharmaceuticals5/9/2025Reiterated Rating$4.33$17.00Outperform$0.0000.00% ROIZURAZura Bio5/9/2025Lower Price Target$1.22$17.00Outperform$0.0000.00% ROIIMCRImmunocore5/8/2025Boost Price Target$29.31$86.00Outperform$0.0000.00% ROICRBPCorbus Pharmaceuticals5/7/2025Lower Price Target$6.31$56.00Outperform$0.0000.00% ROIZURAZura Bio3/26/2025Reiterated Rating$1.37$19.00Outperform$0.0000.00% ROICRVSCorvus Pharmaceuticals3/26/2025Reiterated Rating$3.34$15.00Outperform$0.0000.00% ROIALMSAlumis1/30/2025Initiated Coverage$6.53$32.00Outperform$0.0000.00% ROIEVHEvolent Health1/24/2025Lower Price Target$10.36$18.00Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
